Table S2. Clinicopathological information of excluded patients.
| Characteristics | n (%) | P | |
| Included patients (N=2,141) | Excluded patients (N=1,338) | ||
| IDC, invasive ductal carcinoma; NA, not available; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal receptor 2. | |||
| Age (year) | 0.292 | ||
| <50 | 1,028 (48.01) | 667 (49.85) | |
| ≥50 | 1,113 (51.99) | 671 (50.15) | |
| Menstruation | 0.490 | ||
| Pre-menopausal | 1,149 (53.67) | 702 (52.47) | |
| Post-menopausal | 992 (46.33) | 636 (47.53) | |
| Histology | <0.001 | ||
| IDC | 2,032 (94.91) | 1,210 (90.43) | |
| Non-IDC | 109 (5.09) | 128 (9.57) | |
| Grade | <0.001 | ||
| I | 327 (15.27) | 186 (13.90) | |
| II | 1,264 (59.04) | 631 (47.16) | |
| III | 550 (25.69) | 101 (7.55) | |
| NA | 0 (0) | 420 (31.39) | |
| ER | 0.721 | ||
| Negative | 678 (31.67) | 300 (22.42) | |
| Positive | 1,463 (68.33) | 667 (49.85) | |
| NA | 0 (0) | 371 (27.73) | |
| PR | <0.001 | ||
| Negative | 832 (38.86) | 296 (22.12) | |
| Positive | 1,309 (61.14) | 671 (50.15) | |
| NA | 0 (0) | 371 (27.73) | |
| Ki67 | 0.062 | ||
| <14% | 261 (12.19) | 90 (6.73) | |
| ≥14% | 1,858 (86.78) | 815 (60.91) | |
| NA | 22 (1.03) | 433 (32.36) | |
| HER2 | 0.199 | ||
| HER2-zero | 433 (20.22) | 178 (13.30) | |
| HER2-low | 995 (46.47) | 381 (28.48) | |
| HER2-positive | 713 (33.30) | 321 (23.99) | |
| NA | 22 (1.03) | 458 (34.23) | |